JIN-A02 Overcomes Tagrisso Resistance via C797S and T790M Targeting

JIN-A02 Overcomes Tagrisso Resistance via C797S and T790M Targeting

JIN-A02 is a fourth-gen EGFR inhibitor targeting EGFR C797S resistance in lung cancer, showing brain activity and tumor regression.

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research - PressReach

SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ — J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Association for Cancer Research (AACR). According to the most recent Journal Citation Reports (2025), the journal has an Impact Factor of 10.2, reflecting its i…

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ — J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Association for Cancer Research (AACR). According to the most recent Journal Citation Reports (2025), […]